Looking to Buy Bristol Myers Squibb Stock on the Dip? Read This First.

Bristol Myers Squibb faces a significant patent cliff, with Revlimid already declining and Eliquis and Opdivo set to lose U.S. patent exclusivity in 2028. Management says the growth portfolio now contributes most revenue, but legacy drugs still account for about 46% of sales and total revenue rose only 1% on a constant-currency basis. The stock may still appeal to income investors given its 4.2% dividend yield, but the article argues the low 9.4x forward P/E reflects real earnings risk rather than obvious undervaluation.

Analysis

BMY is behaving like a classic value trap setup: the headline multiple screens cheap, but the market is correctly discounting a multi-year earnings air-pocket rather than a one-year hiccup. The important second-order effect is not just lost revenue from aging franchises; it is the compression of strategic flexibility exactly when the company is spending heavily on integration, pipeline expansion, and capital returns. That combination usually leads to either slower buyback execution or less room to defend the dividend if development setbacks hit simultaneously.

The real underwriting question is whether the acquired assets can move from “offset” to “accelerate” fast enough before the 2028 exclusivity reset. That is a narrow window, and biotech integration risk is asymmetric: successful launches help gradually, but a single clinical or launch disappointment can force the market to re-rate the stock lower very quickly because the bridge period is already short. In other words, the stock’s downside is front-loaded over the next 12-24 months, while any upside from the growth portfolio likely needs multiple clean readouts and strong commercial uptake.

Contrarianally, the market may be over-anchored on patent cliff fear and underpricing the optionality embedded in the acquisition set, especially if management can credibly show that the new assets are not just defensive but expand the company’s addressable categories. Still, the burden of proof is high: for now, BMY is more of a cash-yield and pipeline execution story than a clean re-acceleration story. The dividend can support the shares, but it does not eliminate the risk of a prolonged multiple de-rating if growth stays in the low-single-digit zone.

Key Decisions for Investors

• Stay tactical rather than structural: avoid initiating a full-size long BMY here; if needed, only buy on a post-earnings drawdown with a 6-12 month horizon and a hard stop if growth portfolio momentum does not improve.
• For income mandates, consider a small BMY starter long only against a basket short of slower-growth large-cap pharma; target the dividend carry, but cap exposure because the next 12-24 months are likely range-bound-to-lower.
• Pair trade idea: long quality cash-generative pharma with cleaner patent visibility, short BMY into any valuation-driven bounce; the relative trade benefits if the market keeps rewarding durability over headline yield.
• Use options if you want exposure: sell cash-secured puts 10-15% below spot into elevated volatility, or buy put spreads into earnings to express the risk that integration disappoints before the next pipeline catalyst.
• Do not underwrite BMY on 2026-2027 earnings multiples; anchor valuation to post-2028 normalized earnings only after evidence that new assets can offset legacy erosion.